JW (Cayman) Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Min Liu
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 2.8yrs |
| Board average tenure | 1.5yrs |
Recent management updates
Recent updates
Take Care Before Jumping Onto JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Even Though It's 26% Cheaper
Nov 12
JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Screens Well But There Might Be A Catch
Sep 25A Piece Of The Puzzle Missing From JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) 34% Share Price Climb
May 10Calculating The Intrinsic Value Of JW (Cayman) Therapeutics Co. Ltd (HKG:2126)
May 03JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?
Feb 03CEO
Min Liu (51 yo)
less than a year
Tenure
Mr. Min Liu has been Chief Executive Officer and Executive Director of JW (Cayman) Therapeutics Co. Ltd. since July 31, 2024. He serves as the Chief Commercial Officer at Innovent Biologics Inc. Mr. Liu is...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Interim Chairman | less than a year | CN¥20.98m | 5.45% HK$ 30.4m | |
| CEO & Executive Director | less than a year | no data | no data | |
| Senior Vice President of Tech Operations | 2.3yrs | no data | no data | |
| Senior VP & Chief Scientific Officer | 2.8yrs | no data | no data | |
| Senior Vice President of Corporate Development | 2.8yrs | no data | no data | |
| Senior Advisor & Acting Chief Medical Officer | no data | no data | no data | |
| Senior VP & Chief Commercial Officer | no data | no data | no data | |
| Senior Vice President of Clinical Sciences & Medical Services | no data | no data | no data | |
| Senior Vice President Of Clinical Research & PMO | no data | no data | no data | |
| Company Secretary | 2.9yrs | no data | no data |
2.8yrs
Average Tenure
46yo
Average Age
Experienced Management: 2126's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Interim Chairman | less than a year | CN¥20.98m | 5.45% HK$ 30.4m | |
| CEO & Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 1.7yrs | CN¥276.00k | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Non-Executive Director | 4.4yrs | CN¥331.00k | 1.42% HK$ 8.0m | |
| Independent Non-Executive Director | 4.1yrs | CN¥224.00k | no data | |
| Non-Executive Director | 1.3yrs | no data | no data | |
| Non-Executive Director | 4.5yrs | no data | no data |
1.5yrs
Average Tenure
56.5yo
Average Age
Experienced Board: 2126's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.